Redcliffe Labs

Positions itself as expanding access to affordable, high-quality diagnostic testing, especially in underserved geographies.

Offers a broad catalogue of routine pathology and specialised tests including genetics/DNA testing.

Combines home sample collection, a network of owned labs, and collection centres/franchise points so patients can choose how they get tested.

Markets on-demand 1-hour home sample collection and same-day report delivery as a speed differentiator.

Direct-to-consumer patients booking home sample collection or visiting collection centres for routine pathology, wellness and genetic tests.

Patients whose testing choices are shaped by physician involvement: Redcliffe markets its health checkup packages as doctor-curated and doctor-trusted, using doctor endorsement as an acquisition signal. (No public source found substantiates a formal clinics/hospitals referral-partner B2B2C arrangement, so the claim is narrowed to what this citation actually supports.)

Underserved smaller-city and semi-urban populations targeted for expansion of affordable diagnostics access.

Healthcare professionals, phlebotomists, lab technicians and entrepreneurial partners who open Redcliffe-branded collection centres under its franchise program.

Every diagnostic test booked comes with a complimentary expert consultation and a personalized diet plan, layering personal medical guidance on top of Redcliffe's digital booking experience.

Redcliffe backs its diagnostic reports with an accuracy guarantee, offering a refund if report accuracy isn't met -- an assurance-based trust mechanism with customers.

Customers manage their own bookings and reports via "My Bookings"/"My Reports" dashboard sections and can use free self-service tools such as BMI, heart health, pre-diabetic, Vitamin D and fever-symptom calculators.

Alongside human support, Redcliffe offers round-the-clock AI-driven assistance to customers on its platform.

Fleet of phlebotomists performing at-home sample collection across cities.

Network of owned, NABL-accredited diagnostic labs processing tests.

Third-party franchise-operated collection centres extending reach into new cities under the Redcliffe brand.

Redcliffe offers a dedicated mobile app (downloadable via QR code) for booking tests, managing accounts and accessing exclusive offers, alongside web-based online booking.

Redcliffe runs end-to-end logistics for moving patient samples from homes and collection centres into its lab network for processing.

Core daily operation is processing diagnostic tests at scale across its lab network, reported at over 250,000 test parameters processed per day.

Redcliffe developed and launched India's first commercial drone corridor for diagnostic sample transport, connecting Uttarkashi to Dehradun to speed up sample logistics from hill/remote areas.

Beyond organic growth, Redcliffe actively acquires financially strong regional diagnostic labs -- such as Celara Diagnostics in September 2024 -- to expand its footprint and strengthen cash flow and profitability.

Physical network of owned labs plus franchise collection centres and pickup points across India.

In-house/franchise phlebotomist workforce enabling home sample collection at scale.

Integrated CRM and technology stack supporting franchise operations and logistics for sample management.

Danish development finance institution; led the $42 Mn Series C round with a $20 Mn commitment.

Existing investor that led the $61 Mn Series B and contributed $15 Mn to the Series C.

World Bank Group's private-sector arm; disclosed a proposed equity investment of up to $30 million via compulsorily convertible debentures, pending approval as of April 2026.

Bengaluru-based radiology and pathology provider acquired by Redcliffe Labs for up to Rs 60 crore ($7 Mn); Redcliffe's second acquisition of 2024, part of a roll-up strategy targeting financially strong labs per founder Dheeraj Jain. The source confirms Celara is Bengaluru-based but does not state a South-India-expansion rationale for this specific deal.

The large majority of operating revenue comes from pathology/lab test fees.

Smaller revenue line from sale of health/diagnostics-related products.

Redcliffe runs a franchise program for collection centres, but public financial disclosures don't break out franchise-specific revenue separately from the pathology-testing and product-sales lines above. The cited page markets franchisee (partner) economics -- not Redcliffe's own fee structure -- so this is filed as a likely but unconfirmed revenue channel rather than a verified one.

Advertising costs fell 45% year-on-year to Rs 65.38 crore in FY24, still a major cost line as the company spends to acquire patients directly.

Cost of materials and testing consumables, a direct cost of running diagnostics operations, declined 15% to Rs 106.31 crore in FY24.

Laboratory test charges and depreciation both rose sharply in FY24 -- test charges by 62.2% and depreciation by roughly 3x -- even as total expenses fell overall.

Total expenses were Rs 556.16 crore in FY24, down 14% from Rs 647.30 crore in FY23; net loss narrowed 28% to Rs 250 crore, though EBITDA margin remained deeply negative at -57.55%.